根治性肾切除术后干扰素 α治疗肾癌的临床研究-外科学(泌尿外科学)专业论文.docxVIP

PAGE PAGE 10 新疆医科大学硕士学位论文 Radical Nephrectomy Renal Cell Carcinoma Treated with IFN - α Graduate Clinical Research Postgraduate: Li Tao Supervisor: Ass Prof. Ma Bin Abstract Objective: To investigate patients with renal cell carcinoma after radical nephrectomy treated with IFN-α clinical efficacy and safety. Methods: From January 2002 to January 2009 at the first ,the Second and caner Affiliated Hospital of Xinjiang Medical University, underwent open radical nephrectomy, pathologically confirmed renal cell carcinoma, 86 cases in which postoperative adjuvant therapy with interferon-α 42 cases, not interferon-α therapy in 44 cases, induction and statistical analysis of the impact on survival. Results: IFN-α group of patients with renal cell carcinoma patients after 1 year survival of 41 patients after 2 years, 40 patients were to survive. TNF-α group 1,2 year survival rates were 97.2%, 95.2% of patients 1 year after 3 patients had distant metastasis, 2 years after surgery in patients with distant metastasis in 5 cases. 1, 2 years after the transfer rate was 7.14%, 11.91%. Non-IFN-α group were 1 case of 42-year survival cases, survival of patients after 2 years, 41 cases of IFN-α group of non-application of 1,2-year survival rate of patients with renal cell carcinoma were 95.4%, 91.0% . Patients 1 year after 4 cases of distant metastasis, distant metastasis 2 years after surgery in 6 cases; after 1, 2 years distant metastasis rates were 9.10%, 13.63%. TNF-α group than the survival rate of patients with RCC group is not applied IFN-α, (P＜0.05), the difference was statistically significant. Conclusion: Radical nephrectomy for renal cell carcinoma is recognized as the main method of treatment, but given the radical nephrectomy biological adjuvant therapy of TNF-α, short-term to improve the prognosis of patients and improve survival; interferon-α biological adjuvant therapy, efficacy and side effects safety light. Key words: Renal cell carcinoma; Immune therapy; Int